Greenwich LifeSciences Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
/ 
Frequently asked questions
To buy Greenwich LifeSciences Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Greenwich LifeSciences Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Greenwich LifeSciences Inc. is GLSI:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Greenwich LifeSciences Inc. has its primary listing on NASDAQ. You can trade Greenwich LifeSciences Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Greenwich LifeSciences Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Greenwich LifeSciences Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Greenwich LifeSciences Inc..